Theriva™ Biologics Announces Upcoming Presentations at Medical Meetings [Yahoo! Finance]
McKesson Corporation (MCK)
Last mckesson corporation earnings: 2/4 07:00 am
Check Earnings Report
US:NYSE Investor Relations:
investor.mckesson.com
Company Research
Source: Yahoo! Finance
- SYN-004 Interim blinded safety and pharmacokinetic data to be presented at IDWeek 2025 - Rockville, Md., Oct. 13, 2025 (GLOBE NEWSWIRE) -- Theriva™ Biologics (NYSE American: TOVX), (“Theriva” or the “Company”), a diversified clinical-stage company developing therapeutics designed to treat cancer and related diseases in areas of high unmet need, today announced upcoming presentations at the European Society for Medical Oncology (ESMO 2025) Annual Congress and at Infectious Diseases Week (IDWeek) 2025 Annual Meeting. VCN-01 upcoming mini-oral presentation at ESMO 2025 Expanded data from the VIRAGE trial investigating VCN-01 (zabilugene almadenorepvec) are to be presented at a mini oral session at the ESMO 2025 Congress: Presenting author: Dr. Rocío Garcia-Carbonero, Hospital 12 de Octubre, Madrid, Spain Title: VIRAGE trial: randomized Phase IIb, open-label, study of Nab-Paclitaxel and Gemcitabine with/without intravenous VCN-01 in Patients with Metastatic Pancreatic Cancer
Show less
Read more
Impact Snapshot
Event Time:
MCK
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
MCK alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
MCK alerts
High impacting McKesson Corporation news events
Weekly update
A roundup of the hottest topics
MCK
News
- McKesson (NYSE:MCK) was downgraded by analysts at Zacks Research from a "strong-buy" rating to a "hold" rating.MarketBeat
- McKesson (NYSE:MCK) had its "buy (a-)" rating reaffirmed by analysts at <a style="font-weight:bold" href="https://weissratings.com/">Weiss Ratings</a>.MarketBeat
- Mazdutide 9 mg Achieves Up to 20.1% Weight Loss in Chinese Adults with Obesity, GLORY-2 Study Meets Primary and All Key Secondary Endpoints [Yahoo! Finance]Yahoo! Finance
- McKesson Corporation (MCK) Strong Quarter Spurs Analyst Confidence [Yahoo! Finance]Yahoo! Finance
- McKesson (NYSE:MCK) had its "buy (b+)" rating reaffirmed by analysts at <a style="font-weight:bold" href="https://weissratings.com/">Weiss Ratings</a>.MarketBeat
MCK
Earnings
- 11/5/25 - Beat
MCK
Sec Filings
- 11/17/25 - Form 25-NSE
- 11/10/25 - Form 4
- 11/6/25 - Form 10-Q
- MCK's page on the SEC website